BioCentury | May 8, 2020
Finance

Follow-on market poised for comeback, at least temporarily

...and April follow-ons, 2017-2020 Source: BCIQ: BioCentury Online Intelligence The situation may be improving, however. BMO Capital Markets’...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...now. It will not be chastised like it normally would in an election run-up,” said BMO Capital Markets’...
...It will not be chastised like it normally would in an election run-up.” Phil Capen, BMO Capital Markets...
BioCentury | Feb 6, 2020
Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...to sell 10 million shares at $14-$16. Underwriters are Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

...ClearBridge Investments’ Marshall Gordon told BioCentury. “The appetite for risk has certainly come back,” added BMO Capital Markets’...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...proposed the offering. OptiNose fell $2.01 (18%) to $9.40 Thursday. Jefferies, Cowen, Piper Jaffray and BMO Capital Markets...
BioCentury | Oct 31, 2019
Financial News

Oyster Point, RAPT post gains after pricing IPOs at low end of range

...a postmoney valuation of $349.2 million. The Column Group is its largest shareholder; underwriters are BMO Capital Markets...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...Column Group. Alex Arfaei has joined Pappas Ventures as partner. Arfaei was managing director at BMO Capital Markets...
BioCentury | Jul 25, 2019
Financial News

July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and more

...follow-on Ra Pharmaceuticals Inc. (NASDAQ:RARX) raised $130 million Tuesday in a follow-on underwritten by Jefferies, BMO Capital Markets...
BioCentury | Jul 22, 2019
Financial News

July 22 Financial Quick Takes: Shanghai's rising STAR; plus Retrotrope and RAPT

...at $14-16 on Monday. The offering is underwritten by BofA Merrill Lynch, Wells Fargo Securities, BMO Capital Markets...
BioCentury | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

...$86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Wells Fargo Securities, BMO Capital Markets...
Items per page:
1 - 10 of 552
BioCentury | May 8, 2020
Finance

Follow-on market poised for comeback, at least temporarily

...and April follow-ons, 2017-2020 Source: BCIQ: BioCentury Online Intelligence The situation may be improving, however. BMO Capital Markets’...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...now. It will not be chastised like it normally would in an election run-up,” said BMO Capital Markets’...
...It will not be chastised like it normally would in an election run-up.” Phil Capen, BMO Capital Markets...
BioCentury | Feb 6, 2020
Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...to sell 10 million shares at $14-$16. Underwriters are Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

...ClearBridge Investments’ Marshall Gordon told BioCentury. “The appetite for risk has certainly come back,” added BMO Capital Markets’...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...proposed the offering. OptiNose fell $2.01 (18%) to $9.40 Thursday. Jefferies, Cowen, Piper Jaffray and BMO Capital Markets...
BioCentury | Oct 31, 2019
Financial News

Oyster Point, RAPT post gains after pricing IPOs at low end of range

...a postmoney valuation of $349.2 million. The Column Group is its largest shareholder; underwriters are BMO Capital Markets...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...Column Group. Alex Arfaei has joined Pappas Ventures as partner. Arfaei was managing director at BMO Capital Markets...
BioCentury | Jul 25, 2019
Financial News

July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and more

...follow-on Ra Pharmaceuticals Inc. (NASDAQ:RARX) raised $130 million Tuesday in a follow-on underwritten by Jefferies, BMO Capital Markets...
BioCentury | Jul 22, 2019
Financial News

July 22 Financial Quick Takes: Shanghai's rising STAR; plus Retrotrope and RAPT

...at $14-16 on Monday. The offering is underwritten by BofA Merrill Lynch, Wells Fargo Securities, BMO Capital Markets...
BioCentury | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

...$86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Wells Fargo Securities, BMO Capital Markets...
Items per page:
1 - 10 of 552